Prinston Pharmaceutical, which does business as Solco Healthcare, announced that it has voluntarily recalled several lots of irbesartan and irbesartan HCTZ tablets to treat patients with high BP and HF.
These lots contain a traceable amount of N-nitrosodiethylamine (NDEA), an impurity found in an active pharmaceutical ingredient by Zhejiang Huahai Pharmaceutical that is classified as a probable human carcinogen, according to an announcement from the company. As Cardiology Today previously reported, the impurity is the same as was found in a previous recalls of irbesartan, in addition to the various recalls for valsartan.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.